Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly There were no significant treatment differences between the rosuvastatin and placebo groups for death due to cardiovascular causes or hospitalizations for unstable angina.Rosuvastatin significantly reduced the risk of myocardial infarction (6 fatal events and 62 nonfatal events in placebo-treated subjects vs. 9 fatal events and 22 nonfatal events in rosuvastatin-treated subjects) and the risk of stroke (6 fatal events and 58 nonfatal events in placebo-treated subjects vs. 3 fatal events and 30 nonfatal events in rosuvastatin-treated subjects).In a post-hoc subgroup analysis of JUPITER subjects (n=1405; rosuvastatin=725, placebo=680) with a hsCRP ≥2 mg/L and no other traditional risk factors (smoking, BP ≥140/90 or taking antihypertensives, low HDL‑C) other than age, after adjustment for high HDL‑C, there was no significant treatment benefit with rosuvastatin treatment.At one year, rosuvastatin increased HDL‑C and reduced LDL‑C, hsCRP, total cholesterol and serum triglyceride levels (p<0.001 for all versus placebo).Store at controlled room temperature, 20‑25ºC (68-77ºF) [see USP Controlled Room Temperature]. A total of 13 patients completed both treatment periods of the randomized cross-over phase; one patient withdrew consent due to inability to have blood drawn during the cross-over phase.Crestor 20 mg significantly reduced LDL-C, total cholesterol, ApoB, and non-HDL-C compared to placebo (Table 11).% Difference estimates are based on transformations of the estimated mean difference in log LDL measurements between Crestor and placebo using a mixed model adjusted for study periodIn a double-blind, randomized, multicenter, placebo-controlled, 12-week study, 176 (97 male and 79 female) children and adolescents with heterozygous familial hypercholesterolemia were randomized to rosuvastatin 5, 10 or 20 mg or placebo daily. It is often used in gastroesophageal reflux disease. It may harm them.You can ask your pharmacist or doctor for information about Crestor that is written for health professionals.Crestor is a trademark of the AstraZeneca group of companies.For more information, go to the Crestor website at www.Crestor.com or call 1-800-Crestor.This Patient Information has been approved by the U.S. Food and Drug Administration                             Revised 5/2020The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.

Mehr zum Thema Edema, hemorrhage, and partial necrosis in the interstitium of the choroid plexus was observed in a female dog sacrificed moribund at day 24 at 90 mg/kg/day by oral gavage (systemic exposures 100 times the human exposure at 40 mg/day based on AUC). The data presented in this PAR with regard to Crestor also apply to the dossiers of Cirantan, Provisacor If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with Crestor, promptly interrupt therapy. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. An increased incidence of hepatocellular tumors was not seen at lower doses.Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. 2001;58(11) © 2001  American Society of Health-System Pharmacists a GERD = gastroesophageal reflux disease, PAZ = pantoprazole, RAN = ranitidine, R = randomized, DB = double-blind, P = prospective, MC = multicenter, NIZ = nizatidine, EE = erosive esophagitis, OMZ = omeprazole, Par = parallel group, C = crossover.a PAZ = pantoprazole, RAN = ranitidine, R = randomized, DB = double-blind, Par = parallel group, MC = multicenter, SC = single center, OMZ = omeprazole.a PAZ = pantoprazole, RAN = ranitidine, R = randomized, DB = double-blind, MC = multicenter, Par = parallel group, OMZ = omeprazole.a OMZ 40 = omeprazole 20 mg twice daily, PAZ 40 = pantoprazole 40 mg once daily, PAZ 80 = pantoprazole 40 mg twice daily.a Only adverse events with an incidence greater than or equal to the comparators are shown. You must declare any conflicts of interest related to your comments and responses. Patients treated with 5 mg, 10 mg, and 20 mg daily Crestor had an adverse experience profile generally similar to that of patients treated with placebo.

The following laboratory abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria In the METEOR study, involving 981 participants treated with rosuvastatin 40 mg (n=700) or placebo (n=281) with a mean treatment duration of 1.7 years, 5.6% of subjects treated with Crestor versus 2.8% of placebo-treated subjects discontinued due to adverse reactions.